Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04728321
What this trial is testing

Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Akeso 32
Testing effectiveness (Phase 2)Looking for participantsNCT07208773
What this trial is testing

YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsNon Small Cell Lung CancerSmall Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT04556253
What this trial is testing

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Who this might be right for
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Peking University 47
Testing effectiveness (Phase 2)Ended earlyNCT05090566
What this trial is testing

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557098
What this trial is testing

Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 194
Testing effectiveness (Phase 2)WithdrawnNCT03524274
What this trial is testing

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer

Who this might be right for
Advanced Colorectal Cancer
Fuda Cancer Hospital, Guangzhou
Testing effectiveness (Phase 2)Study completedNCT03038880
What this trial is testing

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

Who this might be right for
Neovascularization, ChoroidalMacular Degeneration, Age-Related
Hoffmann-La Roche 76
Testing effectiveness (Phase 2)WithdrawnNCT01138579
What this trial is testing

Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation

Who this might be right for
LeukemiaStem Cell Transplantation
Technical University of Munich
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07648459
What this trial is testing

CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07644208
What this trial is testing

PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy

Who this might be right for
Hepatocellular Carcinoma (HCC)
Shanghai Zhongshan Hospital 30
Large-scale testing (Phase 3)Looking for participantsNCT06712316
What this trial is testing

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 1,580
Testing effectiveness (Phase 2)WithdrawnNCT03540199
What this trial is testing

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

Who this might be right for
Advanced Kidney Cancer
Fuda Cancer Hospital, Guangzhou
Early research (Phase 1)Study completedNCT03269136
What this trial is testing

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 101
Early research (Phase 1)Study completedNCT05411133
What this trial is testing

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Who this might be right for
Gastrointestinal CancerCholangiocarcinomaLiver Cancer+6 more
Arbele Pty Ltd 33
Testing effectiveness (Phase 2)Ended earlyNCT04496674
What this trial is testing

Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung

Who this might be right for
Lung Cancer Squamous Cell
German Cancer Research Center 3
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07095803
What this trial is testing

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

Who this might be right for
Multiple Advanced Tumors After PD-1 Therapy Failure
Sheng Zhang 60
Early research (Phase 1)WithdrawnNCT02470559
What this trial is testing

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Who this might be right for
Malignant Ovarian Clear Cell TumorMalignant Ovarian Serous TumorRecurrent Fallopian Tube Carcinoma+14 more
Barbara Ann Karmanos Cancer Institute
Early research (Phase 1)UnknownNCT04954456
What this trial is testing

Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies

Who this might be right for
Advanced Malignant Tumor
Qilu Pharmaceutical Co., Ltd. 96
Not applicableNot Yet RecruitingNCT06155422
What this trial is testing

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Gang Chen (101199) 670
Early research (Phase 1)Study completedNCT05028556
What this trial is testing

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

Who this might be right for
Metastatic or Locally Advanced Solid Tumors
Wuhan YZY Biopharma Co., Ltd. 50
Next Page